MX348821B - Polímeros de amina para usarse como secuestrantes del ácido biliar. - Google Patents

Polímeros de amina para usarse como secuestrantes del ácido biliar.

Info

Publication number
MX348821B
MX348821B MX2012009783A MX2012009783A MX348821B MX 348821 B MX348821 B MX 348821B MX 2012009783 A MX2012009783 A MX 2012009783A MX 2012009783 A MX2012009783 A MX 2012009783A MX 348821 B MX348821 B MX 348821B
Authority
MX
Mexico
Prior art keywords
bile acid
amine polymers
acid sequestrants
polymers
binding
Prior art date
Application number
MX2012009783A
Other languages
English (en)
Other versions
MX2012009783A (es
Inventor
Paul Mansky
Eric Connor
Kalpesh Biyani
Scott Hecker
Inez Lees
Yongqi Mu
Felah Salaymeh
Hongmin Zhang
David Bergbreiter
Grace Quaker
Michael James Cope
Elizabeth Goka
Angela Lee
Deidre Madsen
Jun Shao
Xinnan Zhang
Original Assignee
Relypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Relypsa Inc filed Critical Relypsa Inc
Publication of MX2012009783A publication Critical patent/MX2012009783A/es
Publication of MX348821B publication Critical patent/MX348821B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C08G73/0213—Preparatory process
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0246—Polyamines containing other atoms than carbon, hydrogen, nitrogen or oxygen in the main chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0246—Polyamines containing other atoms than carbon, hydrogen, nitrogen or oxygen in the main chain
    • C08G73/0253—Polyamines containing sulfur in the main chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0273—Polyamines containing heterocyclic moieties in the main chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona polímeros de amina reticulados, efectivos para enlazar y eliminar sales biliares del tracto gastrointestinal, estos polímeros enlazantes del ácido biliar o sus composiciones farmacéuticas pueden ser administrados a sujetos para tratar varias enfermedades, incluyendo, hipercolesteremia, diabetes, pruritus, síndrome del intestino irritable - diarrea (ibs-d), malabsorción del ácido biliar y similares.
MX2012009783A 2010-02-24 2011-02-24 Polímeros de amina para usarse como secuestrantes del ácido biliar. MX348821B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30782210P 2010-02-24 2010-02-24
US30782010P 2010-02-24 2010-02-24
US37368210P 2010-08-13 2010-08-13
PCT/US2011/026106 WO2011106548A1 (en) 2010-02-24 2011-02-24 Amine polymers for use as bile acid sequestrants

Publications (2)

Publication Number Publication Date
MX2012009783A MX2012009783A (es) 2012-11-21
MX348821B true MX348821B (es) 2017-06-30

Family

ID=43901141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009783A MX348821B (es) 2010-02-24 2011-02-24 Polímeros de amina para usarse como secuestrantes del ácido biliar.

Country Status (14)

Country Link
US (2) US9655920B2 (es)
EP (1) EP2539389B1 (es)
JP (3) JP6258586B2 (es)
KR (1) KR101822608B1 (es)
CN (2) CN107266681A (es)
AU (2) AU2011220748B2 (es)
BR (1) BR112012021446A2 (es)
CA (1) CA2790901C (es)
DE (1) DE112011100657T5 (es)
ES (1) ES2661079T3 (es)
GB (1) GB2490855A (es)
MX (1) MX348821B (es)
RU (2) RU2612795C2 (es)
WO (1) WO2011106548A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998329A3 (en) 2010-02-24 2016-04-06 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants
US20150239824A1 (en) * 2012-08-24 2015-08-27 Universite De Strasbourg Branched or macrocyclic polyamines and uses thereof
WO2014163883A2 (en) * 2013-03-13 2014-10-09 Elevance Renewable Sciences Natural oil derivatives including primary amine functional groups
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
EP3280421B1 (en) * 2015-04-07 2023-12-27 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
CN105111089B (zh) * 2015-09-07 2017-05-10 南京华威医药科技开发有限公司 吡沙洛姆中间体
CN106176800B (zh) * 2016-07-11 2019-12-06 韩源平 多聚阳离子树脂的制药应用
GB201809627D0 (en) * 2018-06-12 2018-07-25 Biorelevant Com Ltd Methods for preparing buffer solutions suitable for in vitro drug dissolution testing, drug solubility testing and/or drug profiling
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
WO2024040380A1 (zh) * 2022-08-22 2024-02-29 中美华世通生物医药科技(武汉)股份有限公司 铵盐聚合物及其制备方法和作为胆汁酸螯合剂的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
JPH066667A (ja) 1992-06-22 1994-01-14 Canon Inc ぶれ検出装置及びぶれ補正装置
EP0580079B1 (de) 1992-07-22 1996-12-11 Hoechst Aktiengesellschaft Vernetzte, stickstoffhaltige Vinylcopolymere, Verfahren zu ihrer Herstellung sowie die Verwendung dieser Verbindungen
EP0580078B1 (de) 1992-07-22 1997-10-15 Hoechst Aktiengesellschaft Hydrophile Zentren aufweisende Polyvinylamin-Derivate, Verfahren zu ihrer Herstellung sowie die Verwendung der Verbindungen als Arzneimittel, Wirkstoffträger und Nahrungsmittelhilfsstoff
WO1994004596A1 (en) 1992-08-20 1994-03-03 E.I. Du Pont De Nemours And Company Crosslinked polymeric ammonium salts
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
WO1997049387A1 (en) 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US7425579B2 (en) * 1998-04-21 2008-09-16 Universite Laval Methods for inhibiting activity of polyamine transporters
US6294163B1 (en) 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
WO2000038664A2 (en) * 1998-12-23 2000-07-06 Geltex Pharmaceuticals, Inc. Amine condensation polymer bile acid sequestrants
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
EP1699442A2 (en) 2003-12-31 2006-09-13 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
AU2005296290A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Crosslinked amine polymers
JP5089992B2 (ja) * 2005-01-21 2012-12-05 三井化学株式会社 ポリアミン誘導体およびポリオール誘導体
JP2009536246A (ja) * 2006-05-05 2009-10-08 ゲンズイメ コーポレーション ホスフェート捕捉剤としてのアミン縮合重合体
CA2658338A1 (en) 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
US20100234309A1 (en) 2006-09-01 2010-09-16 Genzyme Corporation Dendrimer Compositions
WO2008076242A1 (en) 2006-12-14 2008-06-26 Genzyme Corporation Amido-amine polymer compositions
US20100129309A1 (en) * 2007-02-23 2010-05-27 Dhal Pradeep K Amine polymer compositions
WO2008133954A1 (en) 2007-04-27 2008-11-06 Genzyme Corporation Amido-amine dendrimer compositions
WO2009023544A2 (en) * 2007-08-10 2009-02-19 Ilypsa, Inc. Dosage unit anion-exchange polymer pharmaceutical compositions
JP5332520B2 (ja) * 2007-11-07 2013-11-06 アステラス製薬株式会社 医薬用錠剤
WO2009097127A1 (en) 2008-01-31 2009-08-06 Genzyme Corporation Pharmaceutical compositions
WO2009122400A1 (en) 2008-03-31 2009-10-08 Semorex Inc. Phosphate binding polymers
US20110129433A1 (en) * 2008-06-26 2011-06-02 Ironwood Pharmaceuticals, Inc. Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders
EP2998329A3 (en) 2010-02-24 2016-04-06 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants
WO2011106545A1 (en) 2010-02-24 2011-09-01 Relypsa, Inc. Polyimidazoles for use as bile acid sequestrants

Also Published As

Publication number Publication date
JP6258586B2 (ja) 2018-01-10
CN107266681A (zh) 2017-10-20
MX2012009783A (es) 2012-11-21
ES2661079T3 (es) 2018-03-27
US20140356316A1 (en) 2014-12-04
RU2017106587A (ru) 2019-01-21
CA2790901A1 (en) 2011-09-01
JP6622760B2 (ja) 2019-12-18
AU2016200700B2 (en) 2017-08-17
AU2011220748A1 (en) 2012-09-20
RU2012140432A (ru) 2014-03-27
EP2539389A1 (en) 2013-01-02
US9655920B2 (en) 2017-05-23
KR20120130227A (ko) 2012-11-29
RU2612795C2 (ru) 2017-03-13
BR112012021446A2 (pt) 2016-05-31
DE112011100657T5 (de) 2013-02-28
AU2011220748B2 (en) 2015-11-05
JP2017190464A (ja) 2017-10-19
AU2016200700A1 (en) 2016-02-25
CA2790901C (en) 2018-05-01
JP2016130320A (ja) 2016-07-21
GB201216820D0 (en) 2012-11-07
CN102906159A (zh) 2013-01-30
JP2013520563A (ja) 2013-06-06
KR101822608B1 (ko) 2018-01-29
US20170258825A1 (en) 2017-09-14
CN102906159B (zh) 2017-09-26
EP2539389B1 (en) 2017-12-20
GB2490855A (en) 2012-11-14
WO2011106548A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
GB2490853A (en) Polyimidazoles for use as bile acid sequestrants
GB2490855A (en) Amine polymers for use as bile acid sequestrants
WO2011106542A3 (en) Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants
PH12017500828A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
PH12017500914A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CY1119746T1 (el) Φαρμακευτικες μορφοποιησεις που περιεχουν ριφαξιμινη, διαδικασιες για τη ληψη τους και μεθοδος αγωγης εντερικων νοσων
EA201301292A1 (ru) Применение антител или фрагментов антител против cgrp или против cgrp-r для лечения или профилактики хронических и острых форм диареи
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
WO2013130773A8 (en) Compositions of microbiota and methods related thereto
WO2014097151A3 (en) Autotaxin inhibitors
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
EA201101396A1 (ru) Ингибиторы аутотаксина
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
WO2011150286A3 (en) Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
IL224215A (en) An integrated drug for the treatment of functional diseases or conditions of the gastrointestinal system
WO2010081079A3 (en) Composition and method for treatment of diabetes
UA108636C2 (xx) Пептид
WO2011153234A3 (en) Methods of inhibiting alu rna and therapeutic uses thereof
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2013002212A (es) Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
IN2015DN03229A (es)

Legal Events

Date Code Title Description
FG Grant or registration